In this issue:
R-spondin 2 gene polymorphism predicts FOLFIRI/bevacizumab outcome
Chemotherapy +/- cetuximab for resectable colorectal liver metastasis
TAS-102 with or without bevacizumab for chemorefractory mCRC
Upfront FOLFOXIRI + bevacizumab after progression in mCRC
Maintenance strategies in mCRC
Panitumumab supplementation for CRC
Cetuximab vs bevacizumab in mCRC
Circulating tumour DNA monitoring in advanced CRC of lung and liver metastases
SEER analysis of survival in CRC +/- resection of lung and liver metastases
Aflibercept + fluorouracil, leucovorin, and irinotecan for mCRC
Please login below to download this issue (PDF)